



## **Re-issue of Shares**

NEW YORK and SYDNEY, Australia, 3 July, 2023 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), advises that the Company has re-issued 3,305,000 ordinary shares which was approved by shareholder at the Annual General Meeting held on 31 May 2023.

### **Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001**

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

1. The Company on 30 June 2023 has issued 3,305,000 ordinary shares.
2. The Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;
3. The Company is providing this notice under section 708A(5)(e) of the Corporations Act;
4. As at the date of this notice, the Company has complied with:
  - a. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. Section 674 of the Corporations Act; and
5. As at the date of this notice, other than as disclosed above, there is no information to be disclosed which is excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

The number of ordinary shares on issue as of 30 June 2023 is 79,943,372.

-End-

### **About Beroni Group Limited**

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit [www.beronigroup.com](http://www.beronigroup.com).

### **Forward-Looking Statements Disclaimer**

This press release contains forward-looking statements or forward-looking information, within the meaning of applicable United States and Australian securities laws with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking

statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “intend”, “believe”, “potential” and similar expressions.

Forward-looking information contained in this press release is based on Company management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward-looking statements involve significant risks, uncertainties and assumptions, and there can be no assurance that such statements, or its underlying risks, uncertainties and assumptions will prove to be accurate. Factors that could cause actual results or events to differ materially include, without limitation, risks related to laws, rules and regulation applicable to the Company as well as the industry in which it operates (including in respect of taxes and other levies), economic or market conditions on both a national and global level, currency fluctuations, risks inherent to other entities at a similar stage of development and industry in which the Company currently is, competition from the Company’s competitors, unsatisfactory development or marketing of the Company and/or its products or services, regulatory action or litigation (including product liability claims), and failure to enter into agreements or arrangements with other parties on fair or reasonable terms. Forward-looking information is made only as of the date on which it is provided and, except as may be required by applicable laws, the Company disclaims any intent or obligation to update such forward-looking information whether as a result of new information, future events or otherwise.

For more information, please contact us at:

Tel: +61 2 9159 1827

Email: [enquiry@beronigroup.com](mailto:enquiry@beronigroup.com)

Website: [www.beronigroup.com](http://www.beronigroup.com)